Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed... see more

NDAQ:LMNL - Post Discussion

View:
Post by Dibah420 on Aug 09, 2021 10:35am

L2

 

LIMINAL BIOSCIENCES INC (US: LMNL)


          
Real-time  

Last: 3.87   Change: 1.01    Volume: 20,063,350   Last Trade: 10:33  

  Level ll Quote
  Bid   Ask
  Price   Total Size   # of Orders   Price   Total Size   # of Orders
$3.86 300 2 $3.88 112 1
$3.85 2355 4 $3.89 201 2
$3.84 25 2 $3.90 1284 3
$3.83 130 1 $3.91 3 1
$3.82 300 1 $3.92 278 3
$3.81 223 3 $3.94 11204 6
$3.80 1154 8 $3.95 2438 3
$3.79 1210 2 $3.96 326 3
$3.78 1653 5 $3.97 3130 4
$3.77 540 6 $3.99 6666 8
 
Comment by PLITheOne on Aug 09, 2021 10:37am
Already feel bad for the suckers lined up on the bid side.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities